Replies to post #208119 on Cytodyn Inc (CYDY)

[JPG77]

Wrong again!

Promising Phase II Results for Hard-to-Treat Liver Disease
CytoDyn shared positive results from its Phase II clinical study on the effectiveness of leronlimab against nonalcoholic steatohepatitis (NASH).

The NASH trial achieved the primary endpoint of proton density fat fraction (PDFF) and the secondary endpoint of cT1. PDFF is an MRI-derived biomarker for fatty deposition, while cT1 is an iron-corrected T1 mapping indicator of fibrosis and liver inflammation. Both endpoints were used to assess the NASH risk.

https://www.biospace.com/article/cytodyn-posts-positive-results-from-phase-ii-nash-trial-for-leronlimab/

We do not know if NASH met its end points as the data has not been published.